Product Information
OLANZAPINE-FLUOXETINE 12-50 MG is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $6.5342 per EA under NDC 00093550756. Its NADAC has been published 475 times since Nov 28, 2013.
FDA first approved this application on Jun 19, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50; 12 mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093550756
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FLUOXETINE HYDROCHLORIDE; OLANZAPINEApproval Type
Generic (ANDA)
FDA Application
ANDA077528FDA Approved
6/19/2012
TE Code
AB
On Market Since
6/19/2012
Pharmacological Classes
Price Statistics
The NADAC for OLANZAPINE-FLUOXETINE 12-50 MG has been published 475 times since Nov 28, 2013, and over the history we have for it it has declined 61.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.5342 per EA |
|---|---|
| All-time high | $16.9398 (Dec 11, 2013) |
| All-time low | $5.6431 (Apr 17, 2024) |
| 52-week high | $7.8373 |
| 52-week low | $6.5342 |
| Median price | $10.0320 |
| Average price | $11.2807 |
| Largest weekly change | -33.5% (Apr 17, 2024) |
| Weeks tracked | 475 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Olanzapine and Fluoxetine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Olanzapine and Fluoxetine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLANZAPINE-FLUOXETINE 12-50 MG?
The current National Average Drug Acquisition Cost (NADAC) for OLANZAPINE-FLUOXETINE 12-50 MG, manufactured by Teva Pharmaceuticals USA Inc., is $6.5342 per EA (NDC 00093550756), effective Sep 30, 2026.
How has the price of OLANZAPINE-FLUOXETINE 12-50 MG changed over time?
Over the history we have for it, the NADAC for OLANZAPINE-FLUOXETINE 12-50 MG has declined 61.4%. It has been tracked across 475 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for OLANZAPINE-FLUOXETINE 12-50 MG?
Since Nov 28, 2013, the NADAC for OLANZAPINE-FLUOXETINE 12-50 MG has ranged from a low of $5.6431 (Apr 17, 2024) to a high of $16.9398 (Dec 11, 2013), with a median of $10.0320 per EA.
Are there cheaper alternatives to OLANZAPINE-FLUOXETINE 12-50 MG?
No other NADAC-published product currently shares the active ingredient and strength of OLANZAPINE-FLUOXETINE 12-50 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OLANZAPINE-FLUOXETINE 12-50 MG?
OLANZAPINE-FLUOXETINE 12-50 MG (NDC 00093550756) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.